Found: 23
Select item for more details and to access through your institution.
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results.
- Published in:
- 2019
- By:
- Publication type:
- journal article
International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma – Meet-URO 33 study (REGAL study).
- Published in:
- BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-12319-1
- By:
- Publication type:
- Article
Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b).
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.682449
- By:
- Publication type:
- Article
Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.
- Published in:
- International Journal of Molecular Sciences, 2017, v. 18, n. 9, p. 1967, doi. 10.3390/ijms18091967
- By:
- Publication type:
- Article
Sequential methotrexate/5-fluorouracil in advanced colorectal cancer treatment.
- Published in:
- Journal of Surgical Oncology, 1991, v. 48, p. 129, doi. 10.1002/jso.2930480527
- By:
- Publication type:
- Article
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study).
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211019642
- By:
- Publication type:
- Article
PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective.
- Published in:
- Oncology Letters, 2020, v. 20, n. 4, p. N.PAG, doi. 10.3892/ol.2020.11951
- By:
- Publication type:
- Article
A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum‐Sensitive Ovarian Cancer.
- Published in:
- Oncologist, 2021, v. 26, n. 4, p. e658, doi. 10.1002/onco.13630
- By:
- Publication type:
- Article
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study).
- Published in:
- Clinical Medicine Insights: Oncology, 2021, p. 1, doi. 10.1177/11795549211021667
- By:
- Publication type:
- Article
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study).
- Published in:
- Clinical Medicine Insights: Oncology, 2021, v. 15, p. 1, doi. 10.1177/11795549211021667
- By:
- Publication type:
- Article
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study).
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211019642
- By:
- Publication type:
- Article
Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study.
- Published in:
- Therapeutic Advances in Medical Oncology, 2020, p. 1, doi. 10.1177/1758835920968725
- By:
- Publication type:
- Article
An explainable machine learning model to solid adnexal masses diagnosis based on clinical data and qualitative ultrasound indicators.
- Published in:
- Cancer Medicine, 2024, v. 13, n. 12, p. 1, doi. 10.1002/cam4.7425
- By:
- Publication type:
- Article
Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study.
- Published in:
- Cancer Medicine, 2022, v. 11, n. 16, p. 3084, doi. 10.1002/cam4.4681
- By:
- Publication type:
- Article
Metronomic chemotherapy with cyclophosphamide plus low dose of corticosteroids in advanced castration-resistant prostate cancer across the era of taxanes and new hormonal drugs.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial.
- Published in:
- BMC Cancer, 2006, v. 6, p. 202, doi. 10.1186/1471-2407-6-202
- By:
- Publication type:
- Article
Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI -- Mel.A.) [ISRCTN75125874].
- Published in:
- BMC Cancer, 2006, v. 6, p. 44, doi. 10.1186/1471-2407-6-44
- By:
- Publication type:
- Article
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 9, p. 1, doi. 10.1007/s00262-024-03741-2
- By:
- Publication type:
- Article
An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study.
- Published in:
- Japanese Journal of Clinical Oncology, 2021, v. 51, n. 3, p. 484, doi. 10.1093/jjco/hyaa193
- By:
- Publication type:
- Article
Impact of prior chemotherapy on outcomes with trabectedin/pegylated liposomal doxorubicin in recurrent ovarian cancer.
- Published in:
- Cancer & Chemotherapy Reviews, 2022, v. 17, n. 2, p. 23
- By:
- Publication type:
- Article
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Standardization of CTC AR‐V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression.
- Published in:
- Prostate, 2019, v. 79, n. 1, p. 54, doi. 10.1002/pros.23710
- By:
- Publication type:
- Article
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1307635
- By:
- Publication type:
- Article